Timing is everything: new trial seeks best sequence of targeted therapy for breast cancer
NCT ID NCT07657130
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial is recruiting 120 women with advanced HER2-negative breast cancer to find out whether it is better to receive antibody drug conjugates (ADCs) before chemotherapy or after. Participants will be randomly assigned to one of two sequences, and researchers will compare how long the cancer is controlled, overall survival, side effects, and quality of life. The goal is to optimize treatment timing for better outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
antibody drug conjugates (ADCs) such as trastuzumab deruxtecan or sacituzumab govitecan
What this could lead to
If successful, this trial could help doctors decide the best order to give ADC therapy and chemotherapy, potentially improving how long patients live without their cancer getting worse.
What could go wrong
This is a phase II trial with only 120 participants, so results are preliminary. The best timing may not clearly improve outcomes, and ADCs can cause side effects like nausea or low blood counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER FEMALES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Liaoning Cancer Hospital & Institute
RECRUITINGShenyang, Liaoning, China
Contact Phone: •••-•••-•••• Email: •••••@•••••